Navigation Links
Chary Tamirisa, MD, FACOG, Receives InTone Specialist Certification To Treat Female Urinary Incontinence From InControl Medical, LLC
Date:6/9/2013

Sugar Land, Texas (PRWEB) June 09, 2013

InTone, developed by InControl Medical, LLC, is a medical device available by prescription,indicated for the treatment of stress incontinence, urge incontinence or mixed (stress and urge) incontinence. Available by prescription, InTone combines a daily program of volitional exercises, voice-guided instruction, biofeedback and micro-current stimulation to strengthen muscle tone in the pelvic floor.

Stress incontinence can occur when lifting, sneezing, coughing, laughing or exercising. Urge incontinence is the unwanted and sudden need to urinate. Both can be caused or exacerbated by childbirth, obesity, excessive exercise, lack of exercise, age or trauma.

According to the National Association for Continence, up to 30 million women in America have experienced bladder leakage issues. About one in four new mothers experience “leaking” following normal delivery, and about one in six following cesarean section.

Up to two-thirds of women who “leak” have never mentioned it to their physicians, and up to two-thirds of women do not use any treatment or product to manage their bladder leakage.

Until now, available options had mixed results. Absorbent pads and diapers do nothing to treat the condition. Medications, if prescribed, can cause side effects and are not always effective. Surgery, if performed, is a more invasive option, and is not always effective. Research has shown that even when properly taught how to perform pelvic floor, or Kegel, exercises, about half of all women do them incorrectly.

When asked about treating incontinence Chary Tamirisa, MD, FACOG, stated “I have been waiting many years for a company to create a revolutionary device to strengthen and tone the pelvic floor to prevent female urinary incontinence. InControl Medical has succeeded in this task by combining electrical stimulation and biofeedback technology that is easy for the patient to take and use in the privacy of their home. I am excited that I am the first doctor in Sugarland, Texas to offer this innovative and effective treatment to women.”

After prescribing InTone, the physician customizes the settings for InTone and the patient is shown how to use it at home. A sensor in the unit measures pressure to determine if the patient is doing the exercises properly. The biofeedback unit uses voice-guided instruction to take her through the routine and reports her muscle isolation and strength. Each daily session takes about ten minutes, and data from each session is recorded. After two weeks or so, the physician analyzes the recorded data and adjusts InTone based on the patient’s progress, and at-home treatment sessions continue. Most patients should experience progress in a few weeks, and most patients should experience effective relief in 90 days.

InTone is available by prescription to patients in the United States. InTone was developed by InControl Medical, LLC, based in Brookfield, Wisconsin. InControl Medical provides specialty medical products for women’s health, and is sourced and manufactured entirely in the United States. More information on InTone can be found at http://www.incontrolmedical.com.

To contact Chary Tamirisa, MD, FACOG, please call (281) 277-3300 or visit http://www.sugarlandmedicalandaestheticspa.com.

Read the full story at http://www.prweb.com/releases/2013/6/prweb10812330.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Loyola Cancer Center receives Outstanding Achievement Award
2. MU receives national award for using mind-body approach to improve health
3. Neuropsychologist receives University of Houstons highest faculty honor
4. Boston researcher, surgical oncologist receives national award
5. LA BioMed receives Grand Challenges Explorations grant
6. Lawson researcher receives 1 of first-ever Pfizer Psychiatry Research Awards
7. Dr. Arthur Slutsky, vice-president of research at St. Michaels, receives lifetime award
8. UC San Diego Superfund Research Program receives $15 million grant renewal
9. Markey receives $6.25 million to study deadly blood and bone marrow disease
10. Feola, at University of Kentucky, receives NIH grant to study cystic fibrosis
11. UC Santa Barbaras Kavli Institute receives 2 grants to explore interface of physics and biology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2017)... (PRWEB) , ... June 23, 2017 , ... ... assistance and financial planning services to communities in the greater Chicago metropolitan area, ... to offer assistance to underprivileged youth in Chicago. , Founded in 1897, Hephzibah ...
(Date:6/22/2017)... ... ... Branches, Inc. has been partnering with The Miami Foundation for over 9 ... focused on providing opportunity to low-income families and breaking the cycle of generational poverty. ... to support its , Climb to College & Career initiative which focuses on postsecondary ...
(Date:6/22/2017)... ... June 22, 2017 , ... Children’s ... American Heart Association (AHA) to launch a Rheumatic Heart Disease Center, with the ... diagnosis of rheumatic heart disease (RHD) in high-risk, financially disadvantaged countries and low-income ...
(Date:6/22/2017)... ... 22, 2017 , ... A June 12 article in The Star ... apparent lack of oral hygiene by an aged parent who had recently suffered a ... a number of steps, including scheduling a dentist visit. Northridge Dental Works, a Los ...
(Date:6/20/2017)... ... June 20, 2017 , ... ... announces recipients of its annual “UBBIE” Awards (pronounced you-bee) for 2017. The ... significant achievements toward their involvement with UBA, the clients they serve, and the ...
Breaking Medicine News(10 mins):
(Date:6/14/2017)... HAMPTON, Va. , June 14, 2017  ivWatch ... safety and effectiveness of intravenous (IV) therapy, is pleased ... in the category of Nonsurgical Hospital Supplies and Equipment ... premier awards program for the medtech industry. The award ... at the Jacob K. Javits Center in ...
(Date:6/11/2017)... , June 10, 2017  Eli Lilly and Company ... from three Phase 3 studies of galcanezumab, an investigational ... including late-breaking data on several key secondary endpoints for ... results from these studies (EVOLVE-1, EVOLVE-2 and REGAIN) will ... annual scientific meeting in Boston . ...
(Date:6/8/2017)... 2017   Responding to Heath Ledger,s father,s ... of singer Chris Cornell in May, the mental ... a free online psychiatric drug side effects ... about psychotropic drug risks. The father of ... an accidental overdose, has called for tighter rules on prescription ...
Breaking Medicine Technology: